Xoma Ltd. hired a new chief medical officer and said founder Dr. Patrick Scannon, who worked two years as chief medical officer, shifted to the job of chief scientific officer.
Dr. Paul Rubin, the new chief medical officer of Berkeley-based Xoma (NASDAQ: XOMA), had been in the same job at Funxional Therapeutics Ltd. He was senior vice president of development and later executive vice president of research and development at Sepracor, where he was responsible for development of all internally developed products, such as the sleep drug Lunesta.
No comments:
Post a Comment